{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:30:31Z","timestamp":1791127831064,"version":"4.1.0"},"reference-count":168,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2014.00191","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T07:53:40Z","timestamp":1399362820000},"source":"Crossref","is-referenced-by-count":68,"title":["Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens"],"prefix":"10.3389","volume":"5","author":[{"given":"Harm","family":"Westdorp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette E.","family":"Sk\u00c3\u00b6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit A.","family":"Snijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Franik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasja F.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre P.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,5,6]]},"reference":[{"issue":"4","key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"B2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"issue":"1","key":"B3","first-page":"16","article-title":"The role of immunotherapy in prostate cancer: an overview of current approaches in development","volume":"11","author":"Risk","year":"2009","journal-title":"Rev Urol"},{"issue":"15","key":"B4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"B5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"B6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"6165","key":"B7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"7203","key":"B8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"issue":"1","key":"B9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate cancer and inflammation: the evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"issue":"5","key":"B10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/emmm.201202382","article-title":"Resolution of inflammation: an integrated view","volume":"5","author":"Ortega-Gomez","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"26","key":"B11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"issue":"6917","key":"B12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"1","key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.gde.2009.11.004","article-title":"Inflammation and oncogenesis: a vicious connection","volume":"20","author":"Grivennikov","year":"2010","journal-title":"Curr Opin Genet Dev"},{"issue":"13","key":"B14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/pros.20992","article-title":"Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate","volume":"69","author":"Wang","year":"2009","journal-title":"Prostate"},{"issue":"5","key":"B15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S0090-4295(00)00776-7","article-title":"Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia","volume":"56","author":"Putzi","year":"2000","journal-title":"Urology"},{"issue":"5","key":"B16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/aje\/kwq175","article-title":"Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk","volume":"172","author":"Salinas","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"4","key":"B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5489\/cuaj.1129","article-title":"Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis","volume":"3","author":"Jafari","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"10","key":"B18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/aje\/kwj294","article-title":"Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha","volume":"164","author":"Liu","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"2","key":"B19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/1078-0432.CCR-08-0149","article-title":"Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe","volume":"15","author":"Aggarwal","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"B20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrurol.2011.22","article-title":"The etiology and management of acute prostatitis","volume":"8","author":"Brede","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"1","key":"B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.ede.0000101022.38330.7c","article-title":"Prostatitis as a risk factor for prostate cancer","volume":"15","author":"Roberts","year":"2004","journal-title":"Epidemiology"},{"issue":"3","key":"B22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"B23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0090-4295(97)00456-1","article-title":"Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins","volume":"50","author":"Alexander","year":"1997","journal-title":"Urology"},{"issue":"2","key":"B24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1046\/j.1365-2249.2002.01853.x","article-title":"Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS)","volume":"128","author":"Batstone","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"B25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1586\/eci.09.37","article-title":"Prostate autoimmunity: from experimental models to clinical counterparts","volume":"5","author":"Penna","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"B26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clim.2005.03.011","article-title":"Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients","volume":"116","author":"Motrich","year":"2005","journal-title":"Clin Immunol"},{"issue":"1","key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/1097-0045(20000615)44:149::AID-PROS73.3.CO;2-Z","article-title":"PSA is a candidate self-antigen in autoimmune chronic prostatitis\/chronic pelvic pain syndrome","volume":"44","author":"Ponniah","year":"2000","journal-title":"Prostate"},{"issue":"2\u00e2\u20ac\u201c3","key":"B28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-3083.2007.01971.x","article-title":"Autoimmune prostatitis: state of the art","volume":"66","author":"Motrich","year":"2007","journal-title":"Scand J Immunol"},{"issue":"25","key":"B29","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1073\/pnas.251140998","article-title":"T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer","volume":"98","author":"Mercader","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"B30","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1158\/0008-5472.CAN-07-6229","article-title":"Tumor escape mechanism governed by myeloid-derived suppressor cells","volume":"68","author":"Nagaraj","year":"2008","journal-title":"Cancer Res"},{"issue":"18 Pt 1","key":"B31","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1158\/1078-0432.CCR-07-0182","article-title":"Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy","volume":"13","author":"Talmadge","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"B32","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"182","author":"Ostrand-Rosenberg","year":"2009","journal-title":"J Immunol"},{"issue":"27","key":"B33","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2010.34.5025","article-title":"Immunotherapy for prostate cancer: biology and therapeutic approaches","volume":"29","author":"Cha","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"B34","first-page":"1632","article-title":"A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer","volume":"6","author":"Eder","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"B35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/(SICI)1097-0045(20000501)43:288::AID-PROS33.0.CO;2-G","article-title":"Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer","volume":"43","author":"Meidenbauer","year":"2000","journal-title":"Prostate"},{"issue":"5","key":"B36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00262-003-0451-2","article-title":"Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA","volume":"53","author":"Barrou","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"B37","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-04-2062","article-title":"Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer","volume":"11","author":"Gulley","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"16","key":"B38","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"issue":"19","key":"B39","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"B40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"B41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"B42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/pros.20864","article-title":"The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer","volume":"69","author":"Knight","year":"2009","journal-title":"Prostate"},{"issue":"1","key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/(SICI)1097-0045(19980615)36:139::AID-PROS63.0.CO;2-6","article-title":"Evaluation of phase I\/II clinical trials in prostate cancer with dendritic cells and PSMA peptides","volume":"36","author":"Tjoa","year":"1998","journal-title":"Prostate"},{"issue":"10","key":"B44","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"issue":"12","key":"B45","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00262-006-0157-3","article-title":"Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma","volume":"55","author":"Waeckerle-Men","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"B46","first-page":"2546","article-title":"Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate","volume":"62","author":"Ross","year":"2002","journal-title":"Cancer Res"},{"issue":"16","key":"B47","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1158\/1078-0432.ccr-05-0211","article-title":"High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111\/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody","volume":"11","author":"Richman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol Rev"},{"issue":"4","key":"B49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1158\/1078-0432.CCR-10-1811","article-title":"Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients","volume":"17","author":"Karbach","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"30","key":"B50","doi-asserted-by":"publisher","first-page":"11160","DOI":"10.1073\/pnas.0510834103","article-title":"MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents","volume":"103","author":"Monte","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"B51","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-5347(17)38491-4","article-title":"Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate","volume":"145","author":"Oesterling","year":"1991","journal-title":"J Urol"},{"issue":"2","key":"B52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2003.02.083","article-title":"Biology of prostate-specific antigen","volume":"21","author":"Balk","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"B53","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1073\/pnas.83.10.3166","article-title":"Human prostate-specific antigen: structural and functional similarity with serine proteases","volume":"83","author":"Watt","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"B54","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/pros.21375","article-title":"Enzymatically active prostate-specific antigen promotes growth of human prostate cancers","volume":"71","author":"Williams","year":"2011","journal-title":"Prostate"},{"issue":"3","key":"B55","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/pros.20531","article-title":"Does PSA play a role as a promoting agent during the initiation and\/or progression of prostate cancer?","volume":"67","author":"Williams","year":"2007","journal-title":"Prostate"},{"issue":"5","key":"B56","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1097\/01.ju.0000091264.46134.b7","article-title":"Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen","volume":"170","author":"Aalamian","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"B57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nm0104-26","article-title":"Androgen receptor outwits prostate cancer drugs","volume":"10","author":"Isaacs","year":"2004","journal-title":"Nat Med"},{"issue":"2","key":"B58","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1365-2249.1998.00678.x","article-title":"Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells","volume":"114","author":"Corman","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"22","key":"B59","first-page":"5800","article-title":"A triad of costimulatory molecules synergize to amplify T-cell activation","volume":"59","author":"Hodge","year":"1999","journal-title":"Cancer Res"},{"issue":"7","key":"B60","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"B61","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"B62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jnci\/89.4.293","article-title":"In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen","volume":"89","author":"Correale","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"B63","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/00005392-200208000-00092","article-title":"Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer","volume":"168","author":"Kennedy-Smith","year":"2002","journal-title":"J Urol"},{"issue":"1","key":"B64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00262-005-0110-x","article-title":"Tumor escape mechanisms in prostate cancer","volume":"56","author":"Miller","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"B65","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/jcp.20147","article-title":"Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen","volume":"202","author":"Dallas","year":"2005","journal-title":"J Cell Physiol"},{"issue":"10","key":"B66","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"issue":"5","key":"B67","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"B68","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4062\/biomolther.2012.095","article-title":"Emerging roles of human prostatic acid phosphatase","volume":"21","author":"Kong","year":"2013","journal-title":"Biomol Ther (Seoul)"},{"issue":"7","key":"B69","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1586\/era.10.46","article-title":"Structural and functional analysis of human prostatic acid phosphatase","volume":"10","author":"Hassan","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"B70","first-page":"45","article-title":"Acid phosphatase activity in human semen","volume":"33","author":"Dave","year":"1988","journal-title":"Int J Fertil"},{"issue":"9","key":"B71","first-page":"511","article-title":"Morphological features correlation with serum tumour markers in prostatic carcinoma","volume":"13","author":"Afzal","year":"2003","journal-title":"J Coll Physicians Surg Pak"},{"issue":"5","key":"B72","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00428-009-0759-1","article-title":"Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies","volume":"454","author":"Gunia","year":"2009","journal-title":"Virchows Arch"},{"issue":"1","key":"B73","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0022-5347(17)43003-5","article-title":"Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate","volume":"138","author":"Oesterling","year":"1987","journal-title":"J Urol"},{"issue":"5","key":"B74","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1442-2042.2008.02029.x","article-title":"Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer","volume":"15","author":"Ozu","year":"2008","journal-title":"Int J Urol"},{"issue":"3","key":"B75","first-page":"295","article-title":"Prostatic acid phosphatase expression in human tissues","volume":"4","author":"Graddis","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"B76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0147-0272(91)90005-U","article-title":"Clinical use of tumor markers in oncology","volume":"15","author":"Jacobs","year":"1991","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"B77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ctrv.2009.11.002","article-title":"The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer","volume":"36","author":"Matera","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"B78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/(SICI)1097-0045(19980701)36:2129::AID-PROS83.0.CO;2-D","article-title":"Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide","volume":"36","author":"Peshwa","year":"1998","journal-title":"Prostate"},{"issue":"6","key":"B79","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00262-010-0820-6","article-title":"HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase","volume":"59","author":"Olson","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"B80","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.4049\/jimmunol.167.12.7150","article-title":"Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy","volume":"167","author":"Fong","year":"2001","journal-title":"J Immunol"},{"issue":"7","key":"B81","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/pros.21477","article-title":"Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes","volume":"72","author":"Johnson","year":"2012","journal-title":"Prostate"},{"issue":"2","key":"B82","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3892\/ijo_00000178","article-title":"Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles","volume":"34","author":"Mohamed","year":"2009","journal-title":"Int J Oncol"},{"issue":"11","key":"B83","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00262-009-0699-2","article-title":"An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles","volume":"58","author":"Terasaki","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"B84","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/CJI.0b013e3181dda23e","article-title":"DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer","volume":"33","author":"Becker","year":"2010","journal-title":"J Immunother"},{"issue":"3","key":"B85","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/pros.1066","article-title":"Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer","volume":"47","author":"McNeel","year":"2001","journal-title":"Prostate"},{"issue":"25","key":"B86","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"B87","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer","volume":"25","author":"Mesters","year":"2006","journal-title":"EMBO J"},{"issue":"3","key":"B88","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/CJI.0b013e3181c5495c","article-title":"Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer","volume":"33","author":"Wolf","year":"2010","journal-title":"J Immunother"},{"issue":"2","key":"B89","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pros.10319","article-title":"Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene","volume":"58","author":"O\u00e2\u20ac\u2122Keefe","year":"2004","journal-title":"Prostate"},{"issue":"4","key":"B90","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/1097-0045(20001201)45:4350::AID-PROS103.0.CO;2-U","article-title":"Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells","volume":"45","author":"Lapidus","year":"2000","journal-title":"Prostate"},{"issue":"11","key":"B91","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/(SICI)1097-0142(19981201)83:112259::AID-CNCR53.3.CO;2-K","article-title":"Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen","volume":"83","author":"Murphy","year":"1998","journal-title":"Cancer"},{"issue":"10","key":"B92","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"5","key":"B93","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2006.07.8097","article-title":"Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors","volume":"25","author":"Milowsky","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"B94","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"issue":"21","key":"B95","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"B96","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","article-title":"Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer","volume":"95","author":"Reiter","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"B97","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4049\/jimmunol.144.3.860","article-title":"Role of phosphatidylinositol-anchored proteins in T cell activation","volume":"144","author":"Presky","year":"1990","journal-title":"J Immunol"},{"issue":"10","key":"B98","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.bbamcr.2006.08.008","article-title":"Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine\/growth factor responses","volume":"1763","author":"Rege","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"B99","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1074\/jbc.275.17.12833","article-title":"The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells","volume":"275","author":"Eshel","year":"2000","journal-title":"J Biol Chem"},{"key":"B100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1084\/jem.164.3.709","article-title":"Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies","volume":"164","author":"Malek","year":"1986","journal-title":"J Exp Med"},{"issue":"2","key":"B101","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2306::AID-IJC223.0.CO;2-7","article-title":"Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress","volume":"77","author":"Treister","year":"1998","journal-title":"Int J Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/(SICI)1097-4644(2000)77:34+61::AID-JCB113.3.CO;2-J","article-title":"Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins","volume":"34","author":"Witz","year":"2000","journal-title":"J Cell Biochem Suppl"},{"issue":"3","key":"B103","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1158\/0008-5472.CAN-07-0445","article-title":"Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity","volume":"68","author":"Garcia-Hernandez Mde","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"B104","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/pros.20608","article-title":"Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells","volume":"67","author":"Morgenroth","year":"2007","journal-title":"Prostate"},{"issue":"10","key":"B105","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/ijc.22097","article-title":"Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival","volume":"119","author":"Thomas-Kaskel","year":"2006","journal-title":"Int J Cancer"},{"issue":"5","key":"B106","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1073\/pnas.051624698","article-title":"Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts","volume":"98","author":"Saffran","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"B107","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1016\/j.vaccine.2010.06.093","article-title":"Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice","volume":"28","author":"Huo","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"B108","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"B109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"B110","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/sj.bjc.6603944","article-title":"MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden","volume":"97","author":"Andr\u00c3\u00a9n","year":"2007","journal-title":"Br J Cancer"},{"issue":"7","key":"B111","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10585-005-5376-z","article-title":"MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer","volume":"22","author":"Cozzi","year":"2005","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"B112","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1023\/A:1011379725811","article-title":"MUC1, the renaissance molecule","volume":"6","author":"Gendler","year":"2001","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"18","key":"B113","first-page":"4079","article-title":"Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation","volume":"58","author":"Agrawal","year":"1998","journal-title":"Cancer Res"},{"issue":"10","key":"B114","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.4049\/jimmunol.161.10.5500","article-title":"CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice","volume":"161","author":"Tempero","year":"1998","journal-title":"J Immunol"},{"issue":"12","key":"B115","doi-asserted-by":"publisher","first-page":"7764","DOI":"10.4049\/jimmunol.174.12.7764","article-title":"Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells","volume":"174","author":"Rughetti","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"B116","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5721::AID-IJC163.3.CO;2-E","article-title":"Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation","volume":"82","author":"Chan","year":"1999","journal-title":"Int J Cancer"},{"issue":"12","key":"B117","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00262-007-0335-y","article-title":"A polyvalent vaccine for high-risk prostate patients: \u00e2\u20ac\u0153are more antigens better?\u00e2\u20ac\u009d","volume":"56","author":"Slovin","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"4 Suppl","key":"B118","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1158\/1538-7445.PRCA2012-A16","article-title":"Abstract A16: a phase I\/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients","volume":"72","author":"Major","year":"2012","journal-title":"Cancer Res"},{"issue":"8","key":"B119","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"B120","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/pros.21214","article-title":"Expression of cancer\/testis antigens in prostate cancer is associated with disease progression","volume":"70","author":"Suyama","year":"2010","journal-title":"Prostate"},{"issue":"4","key":"B121","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pros.20025","article-title":"NY-ESO-1 protein expression and humoral immune responses in prostate cancer","volume":"59","author":"Foss\u00c3\u00a5","year":"2004","journal-title":"Prostate"},{"issue":"1","key":"B122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pros.20312","article-title":"Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3\/4, and NY-ESO-1 in cancerous and benign prostatic tissue","volume":"66","author":"Hudolin","year":"2006","journal-title":"Prostate"},{"key":"B123","first-page":"10","article-title":"NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer","volume":"3","author":"Nakada","year":"2003","journal-title":"Cancer Immun"},{"issue":"11","key":"B124","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/testis (CT) antigens: potential targets for immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci"},{"issue":"6","key":"B125","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1073\/pnas.041625098","article-title":"Identification of proacrosin binding protein sp32 precursor as a human cancer\/testis antigen","volume":"98","author":"Ono","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"B126","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1073\/pnas.95.9.5211","article-title":"Identification of a meiosis-specific protein as a member of the class of cancer\/testis antigens","volume":"95","author":"T\u00c3\u00bcreci","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"B127","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1073\/pnas.061507398","article-title":"CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production","volume":"98","author":"Zeng","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"B128","first-page":"779","article-title":"NY-ESO-1 expression and immunogenicity in prostate cancer patients","volume":"89","author":"Gati","year":"2011","journal-title":"Tunis Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res"},{"issue":"2","key":"B130","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","article-title":"Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF","volume":"69","author":"Fong","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"B131","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4049\/jimmunol.165.2.1153","article-title":"Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules","volume":"165","author":"Zeng","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"B132","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10637-013-9960-9","article-title":"HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer","volume":"32","author":"Sonpavde","year":"2013","journal-title":"Invest New Drugs"},{"issue":"7","key":"B133","doi-asserted-by":"publisher","first-page":"e21366","DOI":"10.1371\/journal.pone.0021366","article-title":"MAGE-C2\/CT10 protein expression is an independent predictor of recurrence in prostate cancer","volume":"6","author":"von Boehmer","year":"2011","journal-title":"PLoS One"},{"issue":"16","key":"B134","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cub.2004.07.051","article-title":"Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization","volume":"14","author":"Jin","year":"2004","journal-title":"Curr Biol"},{"issue":"2","key":"B135","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/pros.2990210202","article-title":"Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells","volume":"21","author":"Shah","year":"1992","journal-title":"Prostate"},{"issue":"2","key":"B136","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1210\/en.134.2.596","article-title":"Calcitonin stimulates growth of human prostate-cancer cells through receptor-mediated increase in cyclic adenosine 3\u00e2\u20ac\u00b2,5\u00e2\u20ac\u00b2-monophosphates and cytoplasmic Ca2+ transients","volume":"134","author":"Shah","year":"1994","journal-title":"Endocrinology"},{"issue":"1","key":"B137","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/1097-0215(20010101)91:146::AID-IJC10083.0.CO;2-0","article-title":"Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells","volume":"91","author":"Chien","year":"2001","journal-title":"Int J Cancer"},{"issue":"4","key":"B138","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ijc.21158","article-title":"Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action","volume":"117","author":"Sabbisetti","year":"2005","journal-title":"Int J Cancer"},{"issue":"4","key":"B139","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1365-2141.2007.06940.x","article-title":"AKAP-4: a novel cancer testis antigen for multiple myeloma","volume":"140","author":"Chiriva-Internati","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"B140","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/pros.21400","article-title":"Identification of AKAP-4 as a new cancer\/testis antigen for detection and immunotherapy of prostate cancer","volume":"72","author":"Chiriva-Internati","year":"2012","journal-title":"Prostate"},{"issue":"7","key":"B141","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00262-010-0822-4","article-title":"A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer","volume":"59","author":"Noguchi","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"B142","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0090-4295(01)01405-4","article-title":"Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis","volume":"58","author":"Shariat","year":"2001","journal-title":"Urology"},{"issue":"13","key":"B143","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor \u00e2\u20ac\u201c secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"B144","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"B145","volume-title":"A Phase III Trial of GVAX Immunotherapy for Prostate Cancer Versus Docetaxel Plus Prednisone in Asymptomatic, Castration-Resistant Prostate Cancer (CRPC)","author":"Higano","year":"2009"},{"key":"B146","volume-title":"A Phase III trial of GVAX Immunotherapy for Prostate Cancer in Combination with Docetaxel Versus Docetaxel Plus Prednisone in Symptomatic, Castration-Resistant Prostate Cancer (CRPC)","author":"Small","year":"2009"},{"issue":"5","key":"B147","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"B148","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00262-012-1330-5","article-title":"T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX\/ipilimumab treatment","volume":"62","author":"Santegoets","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"B149","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s00262-006-0161-7","article-title":"Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells","volume":"55","author":"Kyte","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"B150","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/sj.bjc.6602761","article-title":"Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients","volume":"93","author":"Mu","year":"2005","journal-title":"Br J Cancer"},{"issue":"4","key":"B151","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10456-013-9360-y","article-title":"Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2","volume":"16","author":"Conway","year":"2013","journal-title":"Angiogenesis"},{"issue":"1","key":"B152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1479-5876-2-26","article-title":"Cancer immunotherapy: avoiding the road to perdition","volume":"2","author":"Chiriva-Internati","year":"2004","journal-title":"J Transl Med"},{"issue":"1","key":"B153","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1479-5876-9-214","article-title":"Defining the critical hurdles in cancer immunotherapy","volume":"9","author":"Fox","year":"2011","journal-title":"J Transl Med"},{"issue":"5795","key":"B154","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"4","key":"B155","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/PPO.0b013e3181eacbd8","article-title":"Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy","volume":"16","author":"Gajewski","year":"2010","journal-title":"Cancer J"},{"issue":"Suppl 8","key":"B156","doi-asserted-by":"publisher","first-page":"viii47","DOI":"10.1093\/annonc\/mds263","article-title":"Evolution of end points for cancer immunotherapy trials","volume":"23","author":"Hoos","year":"2012","journal-title":"Ann Oncol"},{"issue":"18","key":"B157","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"B158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.cji.0000211341.88835.ae","article-title":"A clinical development paradigm for cancer vaccines and related biologics","volume":"30","author":"Hoos","year":"2007","journal-title":"J Immunother"},{"issue":"2","key":"B159","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B160","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fimmu.2013.00417","article-title":"Clinical implications of co-inhibitory molecule expression in the Tumor microenvironment for DC vaccination: a game of stop and go","volume":"4","author":"Vasaturo","year":"2013","journal-title":"Front Immunol"},{"issue":"8","key":"B161","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"B162","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"B163","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"B164","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1586\/14760584.2013.836911","article-title":"HLA ligandome tumor antigen discovery for personalized vaccine approach","volume":"12","author":"Rammensee","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"B165","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"issue":"7385","key":"B166","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"issue":"32","key":"B167","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"B168","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T22:03:48Z","timestamp":1689199428000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2014.00191\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,6]]},"references-count":168,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2014.00191","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,6]]}}}